FIG. 4.
Western immunoblot analysis of capsids and cells. (a and b) Analysis of capsids isolated from infected control and WAY-150138-treated cells. UL6 staining (a) was performed with sucrose density gradient fractions bracketing the B capsid band, as identified visually on the gradient and by Coomassie staining of fractions for VP5 (lanes labeled Coomassie). The peak B capsid fraction was stained for UL15 (b). Note that staining of both UL6 and UL15 is decreased in capsids from WAY-150138-treated cells compared to those from control cells (No Drug), while the amounts of capsids present (as measured by VP5 staining with Coomassie) are almost the same. (c) Western blot staining for UL6 in uninfected Vero cells (three leftmost lanes) and cells infected with HSV-1 in the absence (middle group of three lanes) and presence (rightmost group of three lanes) of 40 μg of WAY-150138/ml. Samples in each group of three lanes contained 4 × 105, 2 × 105, and 0.8 × 105 cells, respectively. The lane at far right shows the staining of authentic, purified UL6 protein (5). Note that UL6 protein is absent in uninfected cells but present in both control and drug-treated infected cells.